title: Predictive model of venous thromboembolism in endometrial cancer.
abstract: OBJECTIVE
  To profile characteristics and survival of endometrial cancer patients who develop venous thromboembolism (VTE) and to establish a predictive model of VTE in endometrial cancer.
  
  
  METHODS
  Cases were identified using an institutional database between 2000 and 2011. VTE was correlated to clinico-pathological information and survival outcomes. Frequency and odds ratio (OR) of VTE were examined in a predictive model based on combination patterns of independent risk factors for VTE.
  
  
  RESULTS
  VTE was seen in 42 (8.1%, 95% CI 5.8-10.5) out of 516 cases subsequent to the diagnosis of endometrial cancer. Multivariate analysis identified 4 independent risk factors for VTE: elevated CA-125 (hazard ratio [HR] 5.38, p<0.001), extrauterine disease (HR 2.87, p=0.019), thrombocytosis (HR 2.11, p=0.04), and high risk histology (serous and clear cell, HR 2.09, p=0.049). VTE was the strongest variable for decreased progression-free survival (HR 4.28) and the second strongest variable for decreased overall survival (HR 5.65) in multivariate analysis. In a predictive model of VTE, the presence of multiple risk factors was associated with significantly increased risk of VTE: frequency of VTE, 1.4% if no risk factors, 0-9.3% (OR 1.0-4.2) if a single risk factor, 11.1-25.0% (OR 9.0-24.0) if two risk factors, and 42.9-46.2% (OR 54.0-61.7) if ≥3 risk factors.
  
  
  CONCLUSIONS
  VTE represents a surrogate for aggressive disease in endometrial cancer. Multiple risk factors of VTE in our predictive model demonstrated exceedingly high risk of VTE, suggesting that there may be a certain population of endometrial cancer patients who would benefit from long-term anti-coagulant prophylaxis to improve survival outcome.
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA. koji.matsuo@gmail.com
authors.forename: Koji
authors.initials: K
authors.lastname: Matsuo
authors.forename: Annie A
authors.initials: AA
authors.lastname: Yessaian
authors.forename: Yvonne G
authors.initials: YG
authors.lastname: Lin
authors.forename: Huyen Q
authors.initials: HQ
authors.lastname: Pham
authors.forename: Laila I
authors.initials: LI
authors.lastname: Muderspach
authors.forename: Howard A
authors.initials: HA
authors.lastname: Liebman
authors.forename: C Paul
authors.initials: CP
authors.lastname: Morrow
authors.forename: Lynda D
authors.initials: LD
authors.lastname: Roman
mesh_terms: D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000097:blood* / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D015233:Models, Statistical; D011237:Predictive Value of Tests; D011379:Prognosis; D012307:Risk Factors; D016019:Survival Analysis; D054556:Venous Thromboembolism / Q000209:etiology*